Printer Friendly

Zacks Analyst Blog Highlights: Genentech, ImClone, Wipro and MAF Bancorp.

CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Genentech (NYSE: DNA), ImClone (Nasdaq: IMCL), Wipro, Ltd. (NYSE: WIT) and MAF Bancorp (Nasdaq: MAFB).

See the latest posts to the Analyst Blog by visiting: http://at.zacks.com/?id=2673

Here are highlights from Thursday's Analyst Blog:

Genentech with a Lofty Valuation

Genentech (NYSE: DNA) is one of the world's largest biotechnology companies. Genentech's core technology focus is in the area of oncology, but the company develops and markets products for the treatment of cardiovascular diseases, respiratory and endocrine disorders, inflammatory and immune problems, and neurological disorders. New product offerings should make DNA also one of the fastest growing biotechs on the market.

We recommend investors continue to hold the shares. The fundamentals are very solid, but valuation and lofty expectations are a concern. Our price target is $88 per share.

The true growth driver for DNA is blockbuster Avastin (bevacizumab). The drug received approval in early 2004 for the treatment of first-line metastatic colorectal cancer (CRC) in combination with intravenous 5-FU chemotherapy. Penetration in the first-line use is probably at or above 75%. Peak penetration rates are probably around 80%, leaving only modest upside in this use. In early January 2007, ImClone (Nasdaq: IMCL) presented positive data on Erbitux in first-line mCRC [metastatic colorectal carcinoma], so the competitive landscape may heat up in 2008 once ImClone gains approval for this use.

Wipro a Hold Ahead of Earnings

We expect Wipro, Ltd. (NYSE: WIT) to announce a solid fiscal fourth quarter when the company announces its earnings on April 20th. The current weakness in the Indian Rupee against the U.S. dollar (down 2.9% in the fourth quarter compared to the year-ago quarter) could help boost margins and earnings in the quarter, although we remain concerned with the high attrition rates and the company's move to hire less-skilled employees as a means to cut costs. We continue to rate shares of WIT a Hold, and have lowered our price target to $16.75, from our previous $18.50 target, over the next six months.

Wipro had a compounded annual growth rate (CAGR) of 25% over the last five years, exhibiting stability, profitability, and growth from its inception and through down markets for IT services. A solid growth strategy, strategic acquisitions, robust performance of the Global IT Services and Products segment, and a leading position in the Indian Outsourcing market are some of the strengths of Wipro. Wipro's strategy is to expand its range of services in potential growth areas and develop each of those areas as a separate business opportunity.

MAFB Upgraded from Sell to Hold

We are upgrading MAF Bancorp (Nasdaq: MAFB) to a Hold at this time, while lowering our price target by $2. The additional detail provided in the 10-K painted a less attractive picture of the Q4 average balance sheet than we had previously assumed, and our estimates are falling by another $0.03-0.04 per quarter (in addition to the decline that prompted our downgrade).

Pricing now looks much more reasonable relative to peers using either of our primary metrics, but the stock does not look cheap to us even after its significant fall. Peer multiples are likely to ebb and flow as much based on acquisition speculation as on fundamentals, however, which is one reason we have elected to upgrade the shares after a significant pull-back in the group.

MAFB currently trades at 13.3 times the consensus forward estimate (versus 14.1x at the time of our January 30 Note), an 8% premium to the peer group median, vs. a 3% premium at that time. On a price-to-book [P/B] basis, the shares trade at a 13% discount to the peer group median, vs. a 10% discount in late January.

See the latest posts to the Analyst Blog by visiting http://at.zacks.com/?id=2645

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today by visiting http://at.zacks.com/?id=2674.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.
COPYRIGHT 2007 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Apr 13, 2007
Words:899
Previous Article:Xerox Seeks Examples of Excellence for 2007 Global Printing Innovation Awards.
Next Article:Tri-S Security Subsidiary Paragon Systems, Inc. Approved For NATO International Competitive Bidding.
Topics:


Related Articles
Zacks Analyst Blog Highlights: Telmex, Embratel, Lexicon Genetics, Xoma and Genentech.
Zacks Analyst Blog Highlights: Xoma, Ltd., Genentech, AstraZeneca and Cutera.
Zacks Analyst Blog Highlights: CarMax, GM and Ford.
Zacks Analyst Blog Highlights: Pozen, GlaxoSmithKline and Winston Hotels.
Zacks Analyst Blog Highlights: Website Pros and ViroPharma.
Zacks Analyst Blog Highlights: Infosys and National City.
Zacks Analyst Blog Highlights: Abbott Labs, Boston Scientific, Johnson & Johnson, Motorola and Nokia.
Zacks Analyst Blog Highlights: Logitech, Microsoft and Pool Corporation.
Zacks Analyst Blog Highlights: SAP AG, Microsoft and Oracle.
Zacks Analyst Blog Highlights: Castle Brands.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters